List of Lyvispah drug patents
Lyvispah is owned by Amneal.
Lyvispah contains Baclofen.
Lyvispah has a total of 2 drug patents out of which 0 drug patents have expired.
Lyvispah was authorised for market use on 22 November, 2021.
Lyvispah is available in granules;oral dosage forms.
Lyvispah can be used as treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; treatment of spasticity resulting from spinal cord injuries and other spinal cord diseases, method for treating spasticity.
The generics of Lyvispah are possible to be released after 29 September, 2041.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10792262 | AMNEAL | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives |
Jul, 2039
(16 years from now) | |
| US11491125 | AMNEAL | Baclofen formulations and methods of minimizing patient exposure to metabolite variations |
Sep, 2041
(18 years from now) | |
Drugs and Companies using BACLOFEN ingredient
Market Authorisation Date: 22 November, 2021
Treatment: Method for treating spasticity; Treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity; Treatment o...
Dosage: GRANULES;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic